PDS Biotechnology Corporation (PDSB) Income Statement
PDSB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPDSB revenue and net income
PDSB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PDSB quarterly EPS vs estimates
PDS Biotechnology beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.11).
PDSB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $60,518 | $59,791 | $57,326 | $49,078 | $246,388 | $176,292 | $98,414 | $69,118 | $182,918 | $100,117 |
| Gross profit | −$60,518 | −$59,791 | −$57,326 | −$49,078 | −$246,388 | −$176,292 | −$98,414 | −$69,118 | −$183,000 | −$100,000 |
| Research & development | $19.0M | $22.6M | $27.8M | $29.4M | $11.3M | $7.9M | $6.1M | $830,744 | $34.3M | $24.8M |
| Sales, general & admin | $12.5M | $13.8M | $15.3M | $12.2M | $10.2M | $7.0M | $11.0M | $14.3M | $17.7M | $14.7M |
| Total operating expenses | $31.5M | $36.3M | $43.0M | $41.7M | $21.4M | $14.9M | $15.4M | $3.6M | $52.0M | $39.5M |
| Operating income | −$31.5M | −$36.3M | −$43.0M | −$41.7M | −$21.4M | −$14.9M | −$15.5M | −$43.1M | −$52.0M | −$39.5M |
| Interest income | $1.2M | $2.5M | $2.8M | $935,180 | $4,346 | $55,006 | $353,490 | $871,879 | $700,903 | $212,299 |
| Interest expense | $5.3M | $4.7M | $4.2M | $1.3M | $4,346 | $32,953 | $33,559 | $1.4M | $2.2M | $1.2M |
| Income before taxes | −$35.7M | −$38.5M | −$44.3M | −$42.1M | −$21.4M | −$14.8M | −$7.4M | −$3.8M | −$53.4M | −$40.7M |
| Income taxes | −$1.2M | −$869,169 | −$1.4M | −$1.2M | −$4.5M | −$136,000 | −$381,513 | −$2.8M | −$2.6M | −$1.8M |
| Net income | −$34.5M | −$37.6M | −$42.9M | −$40.9M | −$16.9M | −$14.8M | −$7.0M | −$40.9M | −$50.9M | −$38.8M |
| EBITDA | −$30.3M | −$12.7M | −$40.1M | −$40.7M | −$21.4M | −$14.9M | −$7.2M | −$3.6M | −$51.1M | −$39.4M |
| EPS (diluted) | −$0.75 | −$1.03 | −$1.39 | −$1.45 | −$0.81 | −$0.99 | −$1.04 | −$23.99 | −$33.60 | −$27.00 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $59,066 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $15,131 | — | $15,129 | $15,129 | $15,127 | $15,131 | $15,128 | $14,405 | $14,405 | $14,403 |
| Gross profit | — | — | −$15,131 | — | −$15,129 | −$15,129 | −$15,127 | −$15,131 | −$15,128 | −$14,405 | −$14,405 | −$14,403 |
| Research & development | $3.3M | $3.5M | $4.4M | $4.6M | $4.2M | $5.8M | $4.5M | $6.8M | $4.5M | $6.7M | $7.5M | $6.4M |
| Sales, general & admin | $3.2M | $3.06B | $2.3M | $3.6M | $3.4M | $3.3M | $2.8M | $3.4M | $4.2M | $3.4M | $2.9M | $4.1M |
| Total operating expenses | $6.5M | $6.5M | $6.7M | $8.1M | $7.6M | $9.1M | $7.3M | $10.2M | $8.7M | $10.1M | $10.4M | $10.5M |
| Operating income | −$6.5M | −$6.5M | −$6.7M | −$8.1M | −$7.6M | −$9.1M | −$7.4M | −$10.2M | −$8.7M | −$10.1M | −$10.4M | −$10.5M |
| Interest income | $125,405 | $186,814 | $224,659 | $281,109 | $333,624 | $377,849 | $503,942 | $666,770 | $675,209 | $668,895 | $683,540 | $739,404 |
| Interest expense | $3.4M | $1.0M | $1.1M | $1.2M | $2.1M | $930,878 | $1.1M | $1.2M | $1.2M | $1.2M | $1.2M | $1.1M |
| Income before taxes | −$9.8M | −$7.3M | −$7.6M | −$9.0M | −$9.4M | −$9.7M | −$8.0M | −$10.7M | −$9.2M | −$10.6M | −$10.9M | −$10.8M |
| Income taxes | — | — | $2.3M | — | — | −$1.2M | $870.0M | −$10.73B | −$869,169 | $5 | $2 | −$4,733 |
| Net income | −$9.8M | −$7.3M | −$7.6M | −$9.0M | −$9.4M | −$8.5M | −$8.0M | −$10.7M | −$8.3M | −$10.6M | −$10.9M | −$10.8M |
| EBITDA | −$6.5M | −$6.3M | −$6.4M | −$7.9M | −$7.3M | −$8.7M | −$6.8M | −$9.5M | −$8.0M | −$9.4M | −$9.7M | −$9.8M |
| EPS (diluted) | −$0.18 | −$0.13 | −$0.14 | −$0.19 | −$0.21 | −$0.21 | −$0.21 | −$0.29 | −$0.23 | −$0.30 | −$0.35 | −$0.35 |
| Gross margin | — | — | — | — | — | — | −25.6% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −12,461.6% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −13,463.5% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PDSB's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PDSB financial results
PDS Biotechnology reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $34.5 million. Diluted earnings per share came to −$0.75.
See the PDSB stock overview for the latest quote and news, or the PDSB chart for price history and technical indicators.
PDSB income statement FAQ
Does PDS Biotechnology have revenue?
PDS Biotechnology reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is PDS Biotechnology profitable?
No. PDS Biotechnology reported a net loss of $34.5 million in fiscal 2025.
How much does PDS Biotechnology spend on research and development?
PDS Biotechnology spent $19.0 million on research and development in fiscal 2025.
What are PDS Biotechnology's earnings per share?
PDS Biotechnology earned $-0.75 per diluted share in fiscal 2025, compared with $-1.03 a year earlier.
When will PDS Biotechnology report its next earnings?
PDS Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does PDS Biotechnology's fiscal year end?
PDS Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.